Quantitation of metabolic and radiobiological effects of 6- aminonicotinamide in RIF-1 tumor cells in vitro

James C. Street, Alan A. Alfieri, Jason A. Koutcher

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

6-Aminonicotinamide (6AN) can be metabolized to 6-amino-NAD(P+), a competitive inhibitor of NAD(P+)-requiring processes, especially the pentose phosphate pathway (PPP) enzyme, 6-phosphogluconate dehydrogenase. The effect of 6AN on the flux of 1 and 6 13C-labeled glucose to lactate, via glycolysis and the PPP, was investigated using 1H-nuclear magnetic resonance. These studies showed that 6AN as a single agent caused a significant 89% (P < 0.0001) inhibition of glycolytic flux but had no detectable effect on the PPP. 31P-nuclear magnetic resonance studies of perifused RIF-1 cells indicated that 4 h of exposure to 6AN were sufficient to cause significant accumulation of 6-phosphogluconate, the substrate for this enzyme (P < 0.0001). A significant reduction in the phosphocreatine: inorganic phosphate ratio was observed under conditions that led to accumulation of 6-phosphogluconate (P < 0.006). Accumulation of 6- phosphogluconate and subsequent reduction in phosphocreatine correlated with significant potentiation of 6 Gy of irradiation by 6AN. These results suggest that the radiation enhancement effect of 6AN may be due to inhibition of glycolysis (mediated by 6-phosphogluconate) and the associated reduction in high-energy phosphates. Additional studies analyzing the metabolic effects of 6AN in combination with radiation are necessary to determine the role of inhibition of the PPP in 6AN enhancement of radiation.

Original languageEnglish (US)
Pages (from-to)3956-3962
Number of pages7
JournalCancer Research
Volume57
Issue number18
StatePublished - Sep 15 1997
Externally publishedYes

Fingerprint

6-Aminonicotinamide
Pentose Phosphate Pathway
Neoplasms
Phosphocreatine
Glycolysis
Magnetic Resonance Spectroscopy
Phosphates
Radiation
Phosphogluconate Dehydrogenase
In Vitro Techniques
Radiation Effects
Enzymes
NAD
Lactic Acid
Glucose

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Quantitation of metabolic and radiobiological effects of 6- aminonicotinamide in RIF-1 tumor cells in vitro. / Street, James C.; Alfieri, Alan A.; Koutcher, Jason A.

In: Cancer Research, Vol. 57, No. 18, 15.09.1997, p. 3956-3962.

Research output: Contribution to journalArticle

Street, JC, Alfieri, AA & Koutcher, JA 1997, 'Quantitation of metabolic and radiobiological effects of 6- aminonicotinamide in RIF-1 tumor cells in vitro', Cancer Research, vol. 57, no. 18, pp. 3956-3962.
Street, James C. ; Alfieri, Alan A. ; Koutcher, Jason A. / Quantitation of metabolic and radiobiological effects of 6- aminonicotinamide in RIF-1 tumor cells in vitro. In: Cancer Research. 1997 ; Vol. 57, No. 18. pp. 3956-3962.
@article{488b299ae0d44a86944bcf50790db21f,
title = "Quantitation of metabolic and radiobiological effects of 6- aminonicotinamide in RIF-1 tumor cells in vitro",
abstract = "6-Aminonicotinamide (6AN) can be metabolized to 6-amino-NAD(P+), a competitive inhibitor of NAD(P+)-requiring processes, especially the pentose phosphate pathway (PPP) enzyme, 6-phosphogluconate dehydrogenase. The effect of 6AN on the flux of 1 and 6 13C-labeled glucose to lactate, via glycolysis and the PPP, was investigated using 1H-nuclear magnetic resonance. These studies showed that 6AN as a single agent caused a significant 89{\%} (P < 0.0001) inhibition of glycolytic flux but had no detectable effect on the PPP. 31P-nuclear magnetic resonance studies of perifused RIF-1 cells indicated that 4 h of exposure to 6AN were sufficient to cause significant accumulation of 6-phosphogluconate, the substrate for this enzyme (P < 0.0001). A significant reduction in the phosphocreatine: inorganic phosphate ratio was observed under conditions that led to accumulation of 6-phosphogluconate (P < 0.006). Accumulation of 6- phosphogluconate and subsequent reduction in phosphocreatine correlated with significant potentiation of 6 Gy of irradiation by 6AN. These results suggest that the radiation enhancement effect of 6AN may be due to inhibition of glycolysis (mediated by 6-phosphogluconate) and the associated reduction in high-energy phosphates. Additional studies analyzing the metabolic effects of 6AN in combination with radiation are necessary to determine the role of inhibition of the PPP in 6AN enhancement of radiation.",
author = "Street, {James C.} and Alfieri, {Alan A.} and Koutcher, {Jason A.}",
year = "1997",
month = "9",
day = "15",
language = "English (US)",
volume = "57",
pages = "3956--3962",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Quantitation of metabolic and radiobiological effects of 6- aminonicotinamide in RIF-1 tumor cells in vitro

AU - Street, James C.

AU - Alfieri, Alan A.

AU - Koutcher, Jason A.

PY - 1997/9/15

Y1 - 1997/9/15

N2 - 6-Aminonicotinamide (6AN) can be metabolized to 6-amino-NAD(P+), a competitive inhibitor of NAD(P+)-requiring processes, especially the pentose phosphate pathway (PPP) enzyme, 6-phosphogluconate dehydrogenase. The effect of 6AN on the flux of 1 and 6 13C-labeled glucose to lactate, via glycolysis and the PPP, was investigated using 1H-nuclear magnetic resonance. These studies showed that 6AN as a single agent caused a significant 89% (P < 0.0001) inhibition of glycolytic flux but had no detectable effect on the PPP. 31P-nuclear magnetic resonance studies of perifused RIF-1 cells indicated that 4 h of exposure to 6AN were sufficient to cause significant accumulation of 6-phosphogluconate, the substrate for this enzyme (P < 0.0001). A significant reduction in the phosphocreatine: inorganic phosphate ratio was observed under conditions that led to accumulation of 6-phosphogluconate (P < 0.006). Accumulation of 6- phosphogluconate and subsequent reduction in phosphocreatine correlated with significant potentiation of 6 Gy of irradiation by 6AN. These results suggest that the radiation enhancement effect of 6AN may be due to inhibition of glycolysis (mediated by 6-phosphogluconate) and the associated reduction in high-energy phosphates. Additional studies analyzing the metabolic effects of 6AN in combination with radiation are necessary to determine the role of inhibition of the PPP in 6AN enhancement of radiation.

AB - 6-Aminonicotinamide (6AN) can be metabolized to 6-amino-NAD(P+), a competitive inhibitor of NAD(P+)-requiring processes, especially the pentose phosphate pathway (PPP) enzyme, 6-phosphogluconate dehydrogenase. The effect of 6AN on the flux of 1 and 6 13C-labeled glucose to lactate, via glycolysis and the PPP, was investigated using 1H-nuclear magnetic resonance. These studies showed that 6AN as a single agent caused a significant 89% (P < 0.0001) inhibition of glycolytic flux but had no detectable effect on the PPP. 31P-nuclear magnetic resonance studies of perifused RIF-1 cells indicated that 4 h of exposure to 6AN were sufficient to cause significant accumulation of 6-phosphogluconate, the substrate for this enzyme (P < 0.0001). A significant reduction in the phosphocreatine: inorganic phosphate ratio was observed under conditions that led to accumulation of 6-phosphogluconate (P < 0.006). Accumulation of 6- phosphogluconate and subsequent reduction in phosphocreatine correlated with significant potentiation of 6 Gy of irradiation by 6AN. These results suggest that the radiation enhancement effect of 6AN may be due to inhibition of glycolysis (mediated by 6-phosphogluconate) and the associated reduction in high-energy phosphates. Additional studies analyzing the metabolic effects of 6AN in combination with radiation are necessary to determine the role of inhibition of the PPP in 6AN enhancement of radiation.

UR - http://www.scopus.com/inward/record.url?scp=0030823969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030823969&partnerID=8YFLogxK

M3 - Article

C2 - 9307279

AN - SCOPUS:0030823969

VL - 57

SP - 3956

EP - 3962

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 18

ER -